Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands

Idarucizumab

(2015) John W. Eikelboom et al.   CIRCULATION

The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK

(2015) Anamaria Vera Jugrin et al.   THROMBOSIS AND HAEMOSTASIS

Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism

(2014) Bonno van Bellen et al.   CURRENT MEDICAL RESEARCH AND OPINION

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

(2013) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL

(2013) Josien van Es et al.   THROMBOSIS RESEARCH

Introduction to the Ninth Edition

(2012) Gordon H. Guyatt et al.   CHEST

Pulmonary embolism and deep vein thrombosis

(2012) Samuel Z Goldhaber et al.   LANCET

Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands

(2012) Maarten J. Postma et al.   JOURNAL OF MEDICAL ECONOMICS

Catalogue of EQ-5D Scores for the United Kingdom

(2011) Patrick W. Sullivan et al.   MEDICAL DECISION MAKING

Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual

(2009) A. J. TEN CATE-HOEK et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses

(2008) Stephen P McKenna et al.   Health and Quality of Life Outcomes